KALA BIO, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
KALA BIO, INC. (KALA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $7.42 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-15.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-04-15
- KALA BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-03-31 was $6.26, a 6.83% increase year-over-year.
- KALA BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2024-03-31 was $5.86, a 60.41% decline year-over-year.
- KALA BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2023-03-31 was $14.80, a 1581.82% increase year-over-year.
- KALA BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2022-03-31 was $0.88, a 80.09% decline year-over-year.
- KALA BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $7.42, a 28.15% increase from fiscal 2024.
- KALA BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $5.79, a 54.84% decline from fiscal 2023.
- KALA BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $12.82, a 68.27% decline from fiscal 2022.
- KALA BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $40.40, a 77.73% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $7.42 10-K · filed 2026-04-15 | ||||
| 2025-09-30 | $7.42 10-Q · filed 2025-11-19 | ||||
| 2025-06-30 | $6.08 10-Q · filed 2025-08-08 | ||||
| 2025-03-31 | $6.26 10-Q · filed 2025-05-14 | ||||
| 2024-12-31 | $5.79 10-K · filed 2026-04-15 | ||||
| 2024-09-30 | $5.79 10-Q · filed 2024-11-12 | ||||
| 2024-06-30 | $5.81 10-Q · filed 2024-08-06 | ||||
| 2024-03-31 | $5.86 10-Q · filed 2024-05-14 | ||||
| 2023-12-31 | $12.82 10-K · filed 2025-03-31 | ||||
| 2023-09-30 | $12.82 10-Q · filed 2023-11-13 | ||||
| 2023-06-30 | $12.83 10-Q · filed 2023-08-04 | ||||
| 2023-03-31 | $14.80 10-Q · filed 2023-05-09 | ||||
| 2022-12-31 | $40.40 10-K · filed 2024-03-29 | ||||
| 2022-09-30 | $41.12 10-Q · filed 2022-11-08 | ||||
| 2022-06-30 | $0.83 10-Q · filed 2022-08-11 | ||||
| 2022-03-31 | $0.88 10-Q · filed 2022-05-16 | ||||
| 2021-12-31 | $181.43 10-K · filed 2023-03-03 | $3.63 10-K · filed 2022-03-29 | |||
| 2021-09-30 | $3.98 10-Q · filed 2021-11-15 | ||||
| 2021-06-30 | $4.37 10-Q · filed 2021-08-05 | ||||
| 2021-03-31 | $4.42 10-Q · filed 2021-05-05 | ||||
| 2020-12-31 | $3.20 10-K · filed 2022-03-29 | ||||
| 2020-09-30 | $7.06 10-Q · filed 2020-11-05 | $4.00 10-Q · filed 2020-11-05 | |||
| 2020-06-30 | $9.35 10-Q · filed 2020-08-06 | $3.88 10-Q · filed 2020-08-06 | |||
| 2020-03-31 | $3.85 10-Q · filed 2020-05-07 | ||||
| 2019-12-31 | $3.45 10-K · filed 2021-02-25 | ||||
| 2019-09-30 | $2.82 10-Q · filed 2020-11-05 | $3.70 10-Q · filed 2020-11-05 | |||
| 2019-06-30 | $3.71 10-Q · filed 2020-08-06 | $3.71 10-Q · filed 2020-08-06 | |||
| 2019-03-31 | $3.71 10-Q · filed 2020-05-07 | ||||
| 2018-12-31 | $9.05 10-K · filed 2019-03-12 | ||||
| 2018-09-30 | $8.83 10-Q · filed 2019-11-07 | $9.99 10-Q · filed 2019-11-07 | |||
| 2018-06-30 | $11.46 10-Q · filed 2019-08-06 | $10.12 10-Q · filed 2019-08-06 | |||
| 2018-03-31 | $9.25 10-Q · filed 2019-05-09 | ||||
| 2017-12-31 | $9.05 10-K · filed 2020-02-12 | $13.87 10-K · filed 2018-04-02 | |||
| 2017-09-30 | $14.74 10-Q · filed 2018-11-08 | $13.19 10-Q · filed 2017-11-07 | |||
| 2017-06-30 | $3.86 10-Q · filed 2018-08-09 | $3.86 10-Q · filed 2017-08-31 | |||
| 2016-12-31 | $2.71 10-K · filed 2018-04-02 | ||||
| 2016-09-30 | $2.77 10-Q · filed 2017-11-07 | $2.73 10-Q · filed 2017-11-07 | |||
| 2016-06-30 | $3.34 10-Q · filed 2017-08-31 | ||||
| 2015-12-31 | $4.17 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |